Milrinone: A Preliminary Review of its Pharmacological Properties and Therapeutic Use

Drugs

Volumn 36, Issue 2, 1988, Pages 158-192

  Young, Ronald A ^a,b   Ward, Alan ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMRINONE; CAPTOPRIL; CYCLIC AMP; DOBUTAMINE; MILRINONE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE;

ANIMAL EXPERIMENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; HEART INDEX; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

ANIMAL; BLOOD PRESSURE; CARDIOTONIC AGENTS; COMPARATIVE STUDY; HALF-LIFE; HEART FAILURE, CONGESTIVE; HUMAN; MILRINONE; PYRIDONES;

EID: 0023730259     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-198836020-00003     Document Type: Article

References (146)

1. Intravenous and oral cardiotonic activity of Win 47203, a potent amrinone analogue in dogs. Abstract no. 2478
2. Cardiotonic activity of milrinone, a new and potent cardiac bipyridine, on the normal and failing heart of experimental animals
3. Characterization of the cardiotonic effects of milrinone, a new and potent cardiac bipyridine, on isolated tissues from several animal species
4. Correlation of hemodynamic and pharmacokinetic profile of intravenous milrinone in the anesthetized dog
5. Pharmacology of milrinone
6. Possible mechanism of action of milrinone, a new inotropic agent. Abstract no. 3820
7. The role of the muscarinic receptors in the inotropic response to milrinone. Abstract no. 1790
8. Pharmacology of the bipyridines: amrinone and milrinone
9. Occurrence of ventricular arrhythmias in patients receiving acute and chronic infusions of milrinone
10. Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patients with severe congestive heart failure: a multicenter study
11. Parasystole, reentry and tachycardia a canine preparation of cardiac arrhythmias occurring across inexcitable segments of tissue
12. Evaluation of a new bipyridine inotropic agent —milrinone —in patients with severe congestive heart failure
13. Milrinone therapy in patients with severe congestive heart failure: initial hemodynamic and clinical observations
14. Survival of patients with severe congestive heart failure treated with oral milrinone
15. Metabolism and pharmacokinetics of milrinone in laboratory animals
16. Pharmacokinetics and pharmacodynamics of intravenous milrinone. Abstract no. 670
17. Dose-ranging study of intravenous milrinone to determine efficacy and pharmacokinetics
18. Milrinone intravenous pharmacodynamics in heart failure. Abstract
19. Efficacy of milrinone in congestive heart failure
20. Pharmacokinetics and pharmacodynamics of milrinone in chronic congestive heart failure
21. Comparison of intravenous milrinone and dobutamine for congestive heart failure secondary to either ischemic or dilated cardiomyopathy
22. Milrinone (Win 47203): differentiation of its inotropic and vasodilator effects in humans. Abstract
23. Physiologic assessment of the inotropic, vasodilator and afterload reducing effects of milrinone in subjects without cardiac disease
24. Milrinone versus dobutamine: contribution of altered myocardial mechanism and augmented inotropic state to improve left ventricular performance
25. Cardiotonic agents: 1. 4,5-dihydro-6-[4-1H-imidazol-1-yl)phenyl]-3(2H)-pyridazones: novel positive inotropic agents for the treatment of congestive heart failure
26. The positive inotropic response to milrinone in isolated human and guinea-pig myocardium
27. Effect of milrinone on acute myocardial infarct size
28. Evaluation of milrinone and dobutamine in a canine model of acute ischemic left ventricular failure
29. The haemodynamic effects of chronic oral milrinone therapy: a multicenter controlled trial
30. Effects of continuous milrinone infusion on forearm and hepatic blood flows. Abstract
31. Vasodilator properties of milrinone: an intra-arterial study. Abstract
32. Pharmacokinetics of milrinone in congestive heart failure. Abstract A8
33. Ascending dose-range study of oral milrinone in chronic congestive heart failure
34. Dose-ranging and acute hemodynamic response to a new oral inotrope, milrinone, in severe congestive heart failure. Abstract
35. Regional blood flow and neurohormonal responses to chronic milrinone in CHF. Abstract no. 767
36. Identification of the direct vasodilator effect of milrinone with an isolated limb preparation in patients with chronic congestive heart failure
37. Regional blood flow and neurohormonal responses to milrinone in congestive heart failure
38. Milrinone: a positive inotropic vasodilator
39. Vascular versus myocardial effects of intracoronary and intravenous milrinone. Abstract
40. Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness
41. The effects of milrinone on conduction, reflection, and automaticity in canine Purkinje fibers
42. The effects of milrinone on action potential characteristics, conduction, automaticity, and reflected reentry in isolated myocardial fiberts
43. Effects of amrinone and milrinone on single cardiac cells. Abstract no. 239
44. Oral hemodynamic effects of milrinone and enalapril in rats with healed cardiac infarcts
45. Oral milrinone and digoxin in heart failure: results of a placebo-controlled, prospective trial of each agent and the combination
46. Blood flow distribution within skeletal muscle during exercise in the presence of chronic heart failure: effect of milrinone
47. Inhibition of phosphodiesterase by amrinone and milrinone in rat heart. Abstract no. 3070
48. Amrinone and milrinone inhibits cyclic AMP-dependent protein kinase. Abstract no. 1709
49. Biochemical mechanisms for the inotropic effect of the cardiotonic drug, milrinone
50. Inhibition of cyclic AMP-dependent protein kinase activity by the cardiotonic drugs amrinone and milrinone
51. Pharmacokinetics of the bipyridines amrinone and milrinone
52. Milrinone and dobutamine effects on right ventricular preload, afterload and systolic performance in congestive heart failure
53. Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricular muscle
54. Effect of calcium entry blockade with D600 on the cardiotonic activity of milrinone. Abstract no. 4441
55. Effect of milrinone on ventricular arrhythmias in patients with congestive heart failure
56. Hemodynamic and regional blood flow response to milrinone in patients with severe congestive heart failure: a dose-ranging study
57. Milrinone versus dobutamine in congestive heart failure. Abstract
58. Relationship of slow calcium channels to the effects of milrinone on isolated adult myocytes
59. Adverse outcome during long term milrinone for advanced heart failure: a controlled pilot study. Abstract no. 804
60. Electrophysiologic effects of milrinone in patients with congestive heart failure
61. Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure
62. 2+] on the responses to milrinone in rat cardiac preparations
63. Selective dilatation by milrinone and amrinone in coronary arteries. Abstract no. 1786
64. Systemic and coronary effects of intravenous milrinone and dobutamine in congestive heart failure
65. The effects of milrinone and piroximone on intracellular calcium handling in working myocardium from the ferret
66. Pulmonary vascular actions of amrinone and milrinone. Abstract no. 728
67. The vasorelaxant effects of milrinone and other vasodilators are attenuated by ovabain
68. Direct vasodilating action of milrinone and sodium nitrate in the canine coronary artery. Abstract no. 3819
69. Differential inhibition of cardiac cyclic nucleotide phosphodiesterase isozymes by cardiotonic drugs
70. Effect of autonomic blockade on the hemodynamic responses of normal human subjects to acute intravenous milrinone
71. Milrinone augments cardiac ouput indirectly by reflex cardiac stimulation
72. Milrinone in congestive heart failure: observations on ambulatory ventricular arrhythmias
73. Is milrinone only a vasodilator? Abstract
74. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure: dose-response relationships and comparison to nitroprusside
75. The effects of milrinone (Win 47203) on the coronary blood flow and oxygen consumption of the dog heart-lung preparation
76. Role of the contractile proteins and sarcoplasmic reticulum in the response of the heart to catecholamines: an historical review
77. Inotropic support by continuous infusion of milrinone in anesthetised pigs
78. Safety and tolerance studies of intravenous and oral milrinone in normal subjects
79. Long term improvement in exercise hemo-dynamics with milrinone in chronic heart failure. Abstract
80. Acute dose range study of milrinone in congestive heart failure
81. Pharmacokinetics and effects on blood pressure of a single oral dose of milrinone in healthy subjects and in patients with renal impairment
82. Milrinone for long-term therapy of severe heart failure: clinical experience with special reference to maximal exercise tolerance
83. Hemodynamic effects of intravenous and oral milrinone in patients with chronic heart failure
84. Clinical response to long-term milrinone therapy in patients with severe congestive heart failure: 12-month experience
85. Comparative systemic and regional hemodynamic and metabolic effects of angiotensin converting enzyme inhibition with captopril and inotropic therapy with milrinone in heart failure. Abstract
86. Systemic and regional hemodynamic effects of captopril and milrinone administered alone and concomitantly in patients with heart failure
87. Pharmacokinetics and pharmacodynamics of intravenous milrinone. Abstract no. 670
88. Milrinone in the treatment of chronic cardiac failure: a controlled trial
89. Effect of milrinone on complex ventricular arrhythmias in congestive heart failure
90. Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique
91. Milrinone does not improve muscle blood flow during forearm exercise in heart failure
92. Biphasic contractions induced by milrinone in ferret cardiac muscle. Abstract no. 669
93. Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203, in patients with severe congestive heart failure
94. High prevalence of non-sustained ventricular tachycardia in severe congestive heart failure
95. Withdrawal and reinstitution of long-term milrinone therapy: evidence of drug-dependent improvement in cardiac performance without tachyphylaxis
96. Clinical response to long-term milrinone therapy in severe chronic heart failure: two year experience. Abstract no. 671
97. Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial
98. Hemodynamic effects of a new inotropic agent (WIN 47203) in patients with refractory heart failure. Abstract
99. Effects of oral milrinone on end-systolic relations in patients with severe congestive heart failure
100. Milrinone, tobutamine, and nitroprusside: comparative effects on hemodynamics and mycardial energetics in patients with severe congestive heart failure
101. Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone
102. Chronic efficacy of intravenous milrinone in congestive heart failure. Abstract
103. Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure
104. Assessment of long-term therapy with milrinone and the effects of milrinone withdrawal
105. Milrinone, dobutamine, and nitroprusside: comparative effects on hemodynamics and myocardial energetics in patients with severe congestive heart failure
106. 2+-ATPase activity and share structural homologies
107. Mechanism of the positive inotropic effect of milrinone in cultured embryonic chick ventricular cells
108. The search for a digitalis substitute. II: Milrinone (Win 47203). Its action on the heart-lung preparation of the dog
109. Treadmill exercise in assessment of the functional capacity of patients with cardiac disease
110. Studies on the inotropic and chronotropic effects of milrinone in rat and guinea pig Langendorff heart preparations. Abstract no. 1787
111. Myocardial actions of milrinone: characterization of its mechanism of action
112. Preload dependent hemodynamic effects of milrinone in moderate heart failure
113. Exercise responses before and after long-term treatment with oral milrinone in patients with severe heart failure
114. Chronic milrinone therapy: differential effects on maximal and submaximal metabolic responses to exercise in heart failure. Abstract no. 41
115. Acute milrinone therapy in congestive heart failure: lack of correlation between resting hemodynamic response and improvement in exercise capacity. Abstract
116. Effects of milrinone on contractile responses of guinea pig trachea, lung parenchyma and pulmonary artery
117. 2+ adenosine triphosphatase activity: stimulation in vitro by thyroid hormone
118. Long term oral administration of milrinone for dilated cardiomyopathy
119. Phosphodiesterase-inhibiting properties of newer inotropic agents
120. Comparison of effects of dopamine and milrinone on normal and stunned myocardium in conscious dogs
121. DPI 201–106 vs milrinone: haemodynamic responses in an acute canine model of heart failure
122. Effects of the cardiotonic/vasodilator agents, amrinone and milrinone on phosphodiesterase isoenzymes and contractile force in guinea pig cardiac and vascular tissue
123. Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation
124. Long-term therapy with a new cardiotonic agent, WIN 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease
125. The stimulatory effects of milrinone on plasma renin angiotensin system and the response to orthostatic tilt
126. Effect of milrinone on left ventricular performance and myocardial contractility in patients with severe heart failure
127. Oral and intravenous pharmacokinetics of milrinone in human volunteers
128. Pharmacokinetics of milrinone in congestive heart failure patients
129. Effects of amrinone and milrinone on calcium influx into the myocardium
130. Prolonged survival in rats with healed myocardial infarction by enalapril and milrinone
131. Inotropic effects of amrinone and milrinone on contraction and relaxation of isolated cardiac muscle
132. The differential effects of milrinone and dobutamine on regional circulations in congestive heart failure
133. Milrinone therapy in heart failure. Abstract no. 40
134. Inotropic support with milrinone in congestive heart failure. Abstract
135. Milrinone in heart failure: acute effects on left ventricular systolic function and myocardial metabolism
136. Milrinone in heart failure: effects on exercise haemodynamics during short term treatment
137. Renal vascular responses to cardiotonic agents. Abstract no. 1463
138. Acute hemodynamic effects of milrinone in congestive heart failure. Abstract
139. Amrinone: a preliminary review of its pharmacological properties and therapeutic use
140. Reduction in functional mitral regurgitation by amrinone and milrinone in severe left ventricular failure
141. The effect of several ‘new and novel’ cardiotonic agents on key subcellular processes involved in the regulation of myocardial contractility: implications for mechanism of action
142. Acute beneficial effects of milrinone on aerobic capacity, anaerobic threshold and catecholamine response to exercise in heart failure. Abstract
143. Immediate effects of milrinone on metabolic and sympathetic responses to exercise in severe congestive heart failure
144. The pharmacokinetics of milrinone in patients with chronic cardiac failure. Abstract no. A27